Longitudinal trajectory of circulating microRNA-210-3p and its association with low-dose aspirin use in gestational hypertension and preeclampsia: a pilot study

Clin Exp Hypertens. 2026 Dec 31;48(1):2616534. doi: 10.1080/10641963.2026.2616534. Epub 2026 Jan 16.

Abstract

Background: Circulating microRNA-210-3p (miR-210-3p) is a hypoxia-related regulator implicated in placental maladaptation. Its longitudinal behavior across hypertensive disorders of pregnancy (HDP), and whether low-dose aspirin modifies its trajectory, remain insufficiently understood.

Methods: This prospective case-control study was conducted between October 2021 and November 2024. Circulating miR-210-3p was measured in the first trimester and at delivery. Aspirin use followed routine clinical practice for preeclampsia prevention. Longitudinal trajectories were examined using generalized estimating equations (GEE) as the primary analytic approach and linear mixed effects models (LMM) as a secondary method.

Results: Ninety-four women were enrolled, including 73 controls, 11 with gestational hypertension, and 10 with preeclampsia. miR-210-3p increased significantly from the first trimester to delivery in gestational hypertension (p = 0.003) and preeclampsia (p = 0.006), with no significant change in controls. In the first trimester, gestational hypertension exceeded controls (p = 0.006), and preeclampsia exceeded both groups (both p < 0.001). At delivery, gestational hypertension and preeclampsia remained higher than controls (both p < 0.001), and preeclampsia exceeded gestational hypertension (p = 0.036). GEE demonstrated a significantly slower rise in miR-210-3p among aspirin users with gestational hypertension (p = 0.042), and this association strengthened in sensitivity analysis (p = 0.001). LMM showed a similar, non-significant trend.

Conclusion: miR-210-3p exhibited disorder-specific longitudinal patterns across HDP. Aspirin-associated changes were observed in gestational hypertension but not in preeclampsia, suggesting differences in molecular expression trajectories between the two conditions over the course of gestation, while the underlying biological mechanisms remain to be clarified.

Keywords: aspirin; gestational hypertension; hypertensive disorders of pregnancy; microRNA-210-3p; placental hypoxia; preeclampsia.

MeSH terms

  • Adult
  • Aspirin* / administration & dosage
  • Aspirin* / therapeutic use
  • Case-Control Studies
  • Circulating MicroRNA* / blood
  • Female
  • Humans
  • Hypertension, Pregnancy-Induced* / blood
  • Hypertension, Pregnancy-Induced* / drug therapy
  • Longitudinal Studies
  • MicroRNAs* / blood
  • Pilot Projects
  • Pre-Eclampsia* / blood
  • Pre-Eclampsia* / drug therapy
  • Pregnancy
  • Pregnancy Trimester, First
  • Prospective Studies

Substances

  • Aspirin
  • MIRN210 microRNA, human
  • MicroRNAs
  • Circulating MicroRNA